- FUJIFILM Cellular Dynamics has opened a new 175,000-square-foot headquarters and iPSC development and manufacturing facility in Madison, Wisconsin.
- The site is expected to quadruple the company’s iPSC manufacturing capacity and support future contract manufacturing for cell therapy products.
FUJIFILM Cellular Dynamics has opened a new headquarters and induced pluripotent stem cell (iPSC) development and manufacturing facility in Madison, Wisconsin, expanding its capacity for research products and future cell therapy contract manufacturing activities.
The 175,000-square-foot facility is expected to quadruple the company’s manufacturing footprint for iPSC-based research products and services. According to the company, the site was designed with scalable infrastructure to support a range of activities from investigational manufacturing through commercial cell therapy production. The facility will also expand manufacturing of the company’s iPSC-derived iCell product lines used in drug discovery and new approach methods (NAMs).
The facility is part of a previously announced $200 million strategic investment by Fujifilm. The site includes cell culture manufacturing laboratories, process development laboratories, and a center of excellence for gene editing. FUJIFILM Cellular Dynamics stated that the expansion is intended to support pharmaceutical companies, research institutions, and academic organizations developing next-generation therapies and drug discovery platforms.
“The opening of this facility is an exciting milestone for FUJIFILM Cellular Dynamics and represents a crucial next step for scaling the infrastructure needed to support the next generation of iPSC-based research and therapeutics in the U.S.”
Tomoyuki Hasegawa, president and CEO of FUJIFILM Cellular Dynamics
Company executives and public officials attended the ribbon-cutting ceremony, including Wisconsin Gov. Tony Evers and representatives from the Wisconsin Economic Development Corporation and the Japanese consulate. FUJIFILM Cellular Dynamics said the facility further strengthens its CDMO and contract manufacturing capabilities while supporting global demand for regenerative medicine and stem cell-based drug development.
